Israel's Chemomab Q4 net loss narrows on lower R&D spend

Overview

• Israel biotech developer's Q4 and full-year operating expenses declined

• Net loss for Q4 and full year narrowed compared to 2024

• Company achieved FDA alignment on Phase 3 trial design for nebokitug in PSC

Outlook

• Chemomab expects cash runway to last through end of Q1 2027

• Chemomab evaluating additional indications for nebokitug based on preclinical efficacy signals

Result Drivers

• LOWER R&D SPENDING - Co said decrease in R&D expenses was due to completion of nebokitug Phase 2 PSC trial

Company press release: ID:nGNX5Rxt1g

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Chemomab Therapeutics Ltd is $17.50, about 775% above its March 18 closing price of $2.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.